A groundbreaking Israeli study has found that GLP-1 medications — the popular class of weight-loss drugs that includes Ozempic and Wegovy — can dramatically reduce the risk of developing obesity-related cancers, surpassing even the benefits of bariatric surgery. The findings, published in The Lancet’s eClinicalMedicine, analyzed thousands of patients with obesity and type 2 diabetes who were prescribed GLP-1 drugs such as liraglutide (Saxenda), exenatide (Byetta), and dulaglutide (Trulicity). The study excluded newer drugs like semaglutide (Ozempic) and tirzepatide (Zepbound), but still showed striking results: patients on GLP-1s were 41% less likely to develop obesity-linked cancers than those who underwent surgical weight loss procedures.
Recent comments